Conjugated Estrogens
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
- Conjugated Estrogens
- Conjugated Estrogens: From Hormone Therapy to Migraine Disorder (Research Question)
Conjugated Estrogens: From Hormone Therapy to Migraine Disorder (Research Question)
One-Sentence Summary
Conjugated estrogens are a hormone therapy. Their registered indication is not stated in the local record supplied. The TxGNN model predicts they may be useful for migraine disorder, but there are no registered clinical trials and only 15 publications, mostly narrative reviews and small observational studies. The literature suggests any benefit is limited to hormone-related (estrogen-withdrawal) migraine, and estrogen also carries thrombosis and stroke concerns.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the SAHPRA record supplied |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 99.77% |
| Evidence Level | L3 |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, conjugated estrogens are an estrogen replacement therapy. Their link to migraine is through estrogen levels, not through a direct anti-migraine mechanism.
The reviews describe falling estrogen (“withdrawal”) as a recognised trigger of menstrual migraine without aura, and perimenopause as a period of higher migraine prevalence. Keeping estrogen levels stable may therefore reduce attacks in selected women, particularly those who also need treatment for menopausal symptoms.
The evidence is mixed. Hormone replacement therapy has both improved and worsened migraine in postmenopausal women, and high estrogen levels can trigger migraine aura. Any benefit appears limited to hormone-related migraine and is not a general migraine effect.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No RCTs were retrieved. The list below has reviews and small observational or clinical studies only. Relevance screening is still pending for all entries.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28994639 | 2018 | Review | Post Reprod Health | Estrogen withdrawal triggers menstrual migraine without aura, while high estrogen can trigger aura. A stable estrogen environment may help estrogen-withdrawal migraine. |
| 29521155 | 2018 | Review | Climacteric | Hormonal fluctuations, especially in perimenopause, are important migraine triggers. Different migraine types are influenced differently. |
| 27251885 | 2016 | Cohort | Neurology | Compared daily sex hormone levels in women with and without migraine. Suggests migraine-specific hormone profiles. |
| 11306204 | 2001 | Cohort | Maturitas | Evaluated how hormone replacement therapy (HRT) affects the course of primary headaches in postmenopausal women. Only the study aim is available. |
| 12390622 | 2002 | Cohort | Headache | Compared three oral HRT schemes on migraine course. The title indicates the effects differed between schemes. |
| 15455962 | 2004 | Clinical study (pilot) | South Med J | Pilot of a prophylactic strategy for menstrual-associated migraine. Design not verified from the title. |
| 1167630 | 1975 | Clinical study | Neurology | Very small study (6 women). Several days of high estrogen exposure were needed to cause withdrawal migraine. Premenstrual oral estrogen, including conjugated equine estrogens, in four women appears not to have significantly helped (abstract truncated). |
| 2046918 | 1991 | Review | Neurology | Review of estrogens, progestins and headache. No abstract available. |
| 2990722 | 1985 | Mechanistic study | Cephalalgia | Estrogen changes modulate central opioid tone, a possible link to postmenopausal migraine. |
| 8309263 | 1994 | Review | Mayo Clin Proc | Compared transdermal and oral estrogen across clinical situations. Relevant to route of administration. |
South Africa Market Information
| Registration Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Reg. No. 27/21.8.2/0021 | Estracombi Tts | Pad (transdermal) | Not stated in the record supplied |
Notes:
- Essential Medicines List (EML) status is not available in the data supplied.
- The single registered product is a transdermal pad. Please verify its active ingredients against the SAHPRA record, because conjugated estrogens are usually given orally. The link between this registration and the drug entry should be confirmed before local decisions rely on it.
Safety Considerations
Safety information from the SAHPRA-approved Professional Information (PI) has not yet been retrieved. No drug interaction records were found. Please refer to the PI for warnings, contraindications and interactions. Report adverse drug reactions to SAHPRA.
Safety signals from the retrieved evidence:
- Venous thrombosis: the literature documents that estrogens increase venous thrombosis risk and can exacerbate thrombophilia. For example, conjugated equine estrogen is linked to activated protein C resistance (PMID 16879211).
- Migraine with aura: estrogen exposure raises ischaemic stroke and thrombosis concerns, which outweigh any unproven benefit.
- Coagulation-related predictions: several other high-scoring TxGNN predictions (antithrombin deficiency, factor V excess, heparin cofactor 2 deficiency, thrombophilia) appear to reflect harm or contraindication associations, not therapeutic opportunities. They should not be treated as repurposing candidates.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence is limited to narrative reviews and small observational studies, with no registered trials. Benefit appears confined to estrogen-withdrawal migraine, and the safety profile (thrombosis, and stroke risk in migraine with aura) is a real concern. Safety screening cannot proceed until the SAHPRA PI data are obtained.
To proceed, the following is needed:
- SAHPRA Professional Information (warnings and contraindications), obtained from the SAHPRA website
- Confirmation of the registered indication and active ingredients of Reg. No. 27/21.8.2/0021
- Mechanism of action data (for example, from DrugBank)
- Manual relevance screening of the retrieved literature
- Controlled clinical evidence (RCTs) in a defined estrogen-withdrawal migraine population, with stratification by aura status and thrombosis risk
This report is for research reference only and does not constitute medical advice. Predicted candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.